病情分析:病情诊断:您所提及的MCF7细胞是乳腺癌研究中常用的一种细胞系,但它本身并不直接代表患者的乳腺癌类型,尤其是三阴性乳腺癌。三阴性乳腺癌是指雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)均为阴性的乳腺癌。 病因分析:乳腺癌的具体病因复杂,涉及遗传、激素、生活方式等多种因素。而MCF7...
MCF7是一种乳腺癌细胞系,属于ER阳性乳腺癌。MCF7细胞系是乳腺癌细胞系中较为常见的一个,它是雌激素受体阳性(ER+)的细胞系,这意味着它对雌激素具有较高的亲和力和依赖性。 MCF7细胞系的分子分型有多种,常见的包括: 1. Luminal A型:这种类型的乳腺癌细胞通常表达高水平的ER和PR(孕激素受体),但HER2基因扩增...
人乳腺癌细胞MCF7是早建立的人乳腺癌细胞系之一,激素受体阳性,ER阳性,PR阳性,HER2阴性,常用于雌激素受体信号通路和肿瘤细胞增殖方面的研究。T47D细胞系也是激素受体阳性细胞系,ER和PR均为阳性,HER2阴性,常用于雌激素受体信号通路和肿瘤细胞迁移方面的研究。MDA-MB-231细胞系是HER2阴性、ER阴性、PR阴性的细胞系,具有...
Unlike P53 positive tumors, Miat expression was upregulated in ER, PR, Her2 positive tumor tissues. Knockdown Miat suppressed breast cancer cell proliferation and caused G1 arrest in cell cycle. Furthermore, downregulation of Miat promoted apoptosis and significantly decreased migration of breast ...
epithelium. These include the ability for MCF-7 cells to process estrogen in the form of estradiol via estrogen receptors in the cell cytoplasm. This results in the MCF-7 cell line being an estrogen receptor (ER) positive cell line. MCF-7 is also progesterone receptor positive and HER2 ...
HER2过表达型以ER.,PR.,HER2+为其免疫表型特点, 高表达基底上皮细胞基因,包括HER 2及HER 2相关基因GRB 7和TRAPl00等,低表达腔上皮细胞基因,TP53的突变率为71%。此型约占女性乳腺癌的 10%。此型患者多已处于疾病晚期,有腋窝淋巴结转移倾向,恶性程度高,对 曲妥珠单抗及化疗敏感,对联合曲妥珠单抗的化疗更加...
The expression of hormone receptors (ERα receptor and PRβ receptor) and the HER2 receptor are key biomarkers for breast cancer subtyping, prognosis, and therapy [1]. However, breast cancer cells express additional families of hormone receptors, especially the nuclear receptor superfamily [2]. The...
(ER/PR-, HER2+, TP53mut). MCF7 cell line, in comparison to the MDA-MB-231 cell line, is a poorly aggressive and non-invasive cell line. Overall, it is being considered to have low metastatic potential. SK-BR-3 cells are the least invasive cells out of the three studied, according...
Further grading, Her2 status, estrogen receptor (ER), progesterone receptor (PR), and luminal classification was performed on the samples (Table 1). The mean age was 58.2 ± 13.3 years. The mean survival was 12.2 years (95% CI: 11.6–12.8 years), and 49 deaths were documented, while a...
HER2− breast cancer cells, ER-alpha (ESR1), as shown in Fig.1A, thus sensitizing the cells to lower doses of TAM compared to the controls. Endocrine treatment is typically thought to be more effective against tumours expressing high ER and/or PR levels [105]. According to the St. ...